Becro M.E.P.E
Becro M.E.P.E is recorded as a service provider in 8 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 8 of 8 trials · Latest update first
Randomized, observer-blind, placebo-controlled, four Parallel Group, Clinical Trial for exploring the Efficacy and Tolerability of two different strengths ketotifen nasal spray (Ketotifen 0.025% and 0.050%) vs sodium cromoglicate nasal spray 2% in Patients with Rhinitis
Sponsor Eudemus Pharmaceuticals Limited
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
A randomized, single-dose, open label, two-treatment, two-sequence, two-period, crossover study under fasting conditions to examine the bioequivalence between Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg inhalation powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 inhalation powder/GSK in healthy volunteers
Sponsor Respirent Pharmaceuticals Co. Ltd.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A randomized, single-dose, open label, two-treatment, two-sequence, two-period, crossover study under fasting conditions to examine the bioequivalence between Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg inhalation powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 inhalation powder/GSK in healthy volunteers.
Sponsor Respirent Pharmaceuticals Co. Ltd.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Therapeutic Non-Inferiority, Randomized, Observer-blind, Active-comparator, Two-arm, Parallel Group, Multi-center Clinical Trial for Comparing the Efficacy and Tolerability of a Generic Fixed Dose Combination of Brimonidine Tartrate 2 mg/ml + Timolol 5 mg/ml Eye Drops versus Combigan® 2 mg/ml + 5 mg/ml Eye Drops in the Treatment of Intraocular Pressure in Patients with Open Angle Glaucoma or Ocular Hypertension
Sponsor OmniVision GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Randomized, Open-label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults with Untreated Diffuse Large B-Cell Lymphoma (ARCHED/GLA 2022-1)
Sponsor University Of Saarland
- Start (EU)
- Latest update
- Estimated end
- Not reported
Non-inferiority Clinical Trial for Comparing the Efficacy and Tolerability of a new fixed-Combination Generic Formulation of Brimonidine 0.2%/Timolol 0.5% eye drops, solution in single-dose containers vs Combigan® eye drops, solution in Patients with Open Angle Glaucoma or Ocular Hypertension
Sponsor Becro (Cyprus) Limited
- Start (EU)
- Latest update
- Estimated end
- Not reported
Pharmacodynamics of IMP 08P2002F0 (Fixed dose combination of 0.34% tropicamide and 2.5% phenylephrine hydrochloride, eye drop, Solution) a new ophthalmic mydriatic solution in healthy volunteers.
Sponsor Unither Pharmaceuticals
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Therapeutic Non-Inferiority, Randomized, Observer-blind, Active-reference, Two-arm, Parallel Group, Multi-center Clinical Trial for Comparing the Efficacy and Tolerability of a Generic Fixed Combination of Brinzolamide 10mg/ml + Timolol 5mg/ml Eye Drops versus Azarga® 10mg/ml + 5mg/ml Eye Drops in the Treatment of Intraocular Pressure in Patients with Open Angle Glaucoma or Ocular Hypertension
Sponsor OmniVision GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Becro M.E.P.E?
The 2026-10-09 snapshot links Becro M.E.P.E to 8 distinct CTIS trials. Recorded services include Clinical monitoring, Project management, Data management, Investigator recruitment, among 16 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Becro M.E.P.E?
The most frequently recorded therapeutic areas are Respiratory, Allergy, Ophthalmology. Recorded phases include Phase 2, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Becro M.E.P.E conducted?
The linked trials record locations in 2 countries, including Greece, Germany. These are trial locations, not confirmed office locations or countries where Becro M.E.P.E delivered services.
What can this page tell me about Becro M.E.P.E's trial experience?
Browse 8 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Becro M.E.P.E. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Becro M.E.P.E.